Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Xavier Castellsagué; Kevin A Ault; F Xavier Bosch; Darron Brown; Jack Cuzick; Daron G Ferris; Elmar A Joura; Suzanne M Garland; Anna R Giuliano; Mauricio Hernandez-Avila; Warner Huh; Ole-Erik Iversen; Susanne K Kjaer; Joaquin Luna; Joseph Monsonego; Nubia Muñoz; Evan Myers; Jorma Paavonen; Punnee Pitisuttihum; Marc Steben; Cosette M Wheeler; Gonzalo Perez; Alfred Saah; Alain Luxembourg; Heather L Sings; Christine Velicer

doi:10.1016/j.pvr.2016.03.002

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region

Papillomavirus Res. 2016 Dec:2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

Authors

Xavier Castellsagué¹, Kevin A Ault², F Xavier Bosch³, Darron Brown⁴, Jack Cuzick⁵, Daron G Ferris⁶, Elmar A Joura⁷, Suzanne M Garland⁸, Anna R Giuliano⁹, Mauricio Hernandez-Avila¹⁰, Warner Huh¹¹, Ole-Erik Iversen¹², Susanne K Kjaer¹³, Joaquin Luna¹⁴, Joseph Monsonego¹⁵, Nubia Muñoz¹⁶, Evan Myers¹⁷, Jorma Paavonen¹⁸, Punnee Pitisuttihum¹⁹, Marc Steben²⁰, Cosette M Wheeler²¹, Gonzalo Perez²², Alfred Saah²³, Alain Luxembourg²³, Heather L Sings²³, Christine Velicer²³

Affiliations

¹ Institut Catala d'Oncologia (ICO), IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Spain. Electronic address: xcastellsague@iconcologia.net.
² Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS, USA.
³ Institut Catala d'Oncologia (ICO), IDIBELL, CIBERESP, L'Hospitalet de Llobregat, Catalonia, Spain.
⁴ Department of Medicine, Indiana University School of Medicine, Indianapolis IN, USA.
⁵ Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.
⁶ Department of Obstetrics and Gynecology, Georgia Regents University Cancer Center, Georgia Regents University, Augusta, GA, USA.
⁷ Department of Gynecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
⁸ Department of Microbiology and Infectious Diseases, The Royal Women׳s Hospital, Murdoch Childrens Research Institute, Department of Obstetrics and Gynecology, University of Melbourne, Australia.
⁹ Moffitt Cancer Center, Tampa, FL, USA.
¹⁰ National Institute of Public Health, Cuernavaca, Morelos, Mexico.
¹¹ Division of Gynecologic Oncology, University of Alabama, Birmingham, AL, USA.
¹² Institute of Clinical Medicine, University of Bergen/Haukeland University Hospital, Bergen, Norway.
¹³ Danish Cancer Society Research Center, Copenhagen Denmark and Department of Gynecology, Rigshospitalet, University of Copenhagen, Denmark.
¹⁴ Department of Obstetrics and Gynecology, Clinica Colsanitas, Fundacion Universitaria Sanitas, Bogota, Colombia.
¹⁵ Institut du col, Paris, France.
¹⁶ National Institute of Cancer, Bogotá, Colombia.
¹⁷ Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
¹⁸ Department of Obstetrics and Gynecology, University Central Hospital, Helsinki, Finland.
¹⁹ Faculty of Tropical Medicine, Mahidol University, Thailand.
²⁰ Direction des Risques Biologiques et de la Santé au travail, Institut National de Santé Publique du Québec, Montréal, QC, Canada.
²¹ Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
²² Merck & Co., Inc., Kenilworth, NJ, USA; Universidad del Rosario, Bogota, Colombia.
²³ Merck & Co., Inc., Kenilworth, NJ, USA.

Abstract

Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region METHODS: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus.

Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3.

Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

Trial registration: ClinicalTrials.gov NCT00092521 NCT00092534 NCT00090220.

Keywords: Adenocarcinoma in situ; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma / virology*
Adolescent
Adult
Asia
Europe
Female
Genotype*
Humans
Latin America
Middle Aged
North America
Papillomaviridae / classification*
Papillomaviridae / genetics
Papillomaviridae / isolation & purification*
Randomized Controlled Trials as Topic
Uterine Cervical Dysplasia / virology*
Young Adult

Associated data

ClinicalTrials.gov/NCT00092521
ClinicalTrials.gov/NCT00092534
ClinicalTrials.gov/NCT00090220

Grants and funding

16891/CRUK_/Cancer Research UK/United Kingdom